Ionis earns $10 million after licensing agreement with Janssen
Ionis Pharmaceuticals, Inc. recently announced $10 million in earnings from Janssen Biotech Inc. after licensing the drug, INOIS-JBI1-2.5Rx, which is designed to hinder an undisclosed target in the gastrointestinal (GI) tract that is used to treat GI autoimmune disease. Read More »